Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT

0 avis

Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT

Archive ouverte

Edité par CCSD ; Springer Verlag -

International audience

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma

Archive ouverte | Mulé, Sébastien | CCSD

International audience

Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients

Archive ouverte | Vermersch, Mathilde | CCSD

International audience. Optimal HCC therapeutic management relies on accurate tumor staging. Our aim was to assess the impact of 18F-FDG-WB-PET/MRI on HCC metastatic staging, compared with the standard of care CT-CA...

Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18 F-FCH to Predict Response to 90 Y Radioembolization in Patients With Hepatocellular Carcinoma

Archive ouverte | Reizine, Edouard | CCSD

International audience

Chargement des enrichissements...